Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Predicting selective drug targets in cancer through metabolic networks.

Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T.

Mol Syst Biol. 2011 Jun 21;7:501. doi: 10.1038/msb.2011.35. Erratum in: Mol Syst Biol. 2011;7. doi:10.1038/msb.2011.51.

PMID:
21694718
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling.

Jerby L, Ruppin E.

Clin Cancer Res. 2012 Oct 15;18(20):5572-84. doi: 10.1158/1078-0432.CCR-12-1856. Review.

PMID:
23071359
[PubMed - indexed for MEDLINE]
Free Article
3.

Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines.

Li L, Zhou X, Ching WK, Wang P.

BMC Bioinformatics. 2010 Oct 8;11:501. doi: 10.1186/1471-2105-11-501.

PMID:
20932284
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Systems biology-defined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status.

Yan B, Chen G, Saigal K, Yang X, Jensen ST, Van Waes C, Stoeckert CJ, Chen Z.

Genome Biol. 2008;9(3):R53. doi: 10.1186/gb-2008-9-3-r53. Epub 2008 Mar 11.

PMID:
18334025
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer.

Knowles LM, Smith JW.

BMC Genomics. 2007 Jun 12;8:168.

PMID:
17565694
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

From oncogene to network addiction: the new frontier of cancer genomics and therapeutics.

Tonon G.

Future Oncol. 2008 Aug;4(4):569-77. doi: 10.2217/14796694.4.4.569. Review.

PMID:
18684067
[PubMed - indexed for MEDLINE]
7.

Integration of cancer gene co-expression network and metabolic network to uncover potential cancer drug targets.

Chen J, Ma M, Shen N, Xi JJ, Tian W.

J Proteome Res. 2013 Jun 7;12(6):2354-64. doi: 10.1021/pr400162t. Epub 2013 May 6.

PMID:
23590569
[PubMed - indexed for MEDLINE]
8.

Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production.

Colijn C, Brandes A, Zucker J, Lun DS, Weiner B, Farhat MR, Cheng TY, Moody DB, Murray M, Galagan JE.

PLoS Comput Biol. 2009 Aug;5(8):e1000489. doi: 10.1371/journal.pcbi.1000489. Epub 2009 Aug 28.

PMID:
19714220
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Functional genomics to explore cancer cell vulnerabilities.

Kahle KT, Kozono D, Ng K, Hsieh G, Zinn PO, Nitta M, Chen CC.

Neurosurg Focus. 2010 Jan;28(1):E5. doi: 10.3171/2009.10.FOCUS09212.

PMID:
20043720
[PubMed - indexed for MEDLINE]
10.

Heterogeneity of tumor-induced gene expression changes in the human metabolic network.

Hu J, Locasale JW, Bielas JH, O'Sullivan J, Sheahan K, Cantley LC, Vander Heiden MG, Vitkup D.

Nat Biotechnol. 2013 Jun;31(6):522-9. doi: 10.1038/nbt.2530. Epub 2013 Apr 21.

PMID:
23604282
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.

Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, Aittokallio T.

PLoS Comput Biol. 2013;9(9):e1003226. doi: 10.1371/journal.pcbi.1003226. Epub 2013 Sep 12.

PMID:
24068907
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Integrated functional, gene expression and genomic analysis for the identification of cancer targets.

Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, Mein CA, Natrajan R, Savage K, Tamber N, Reis-Filho JS, Turner NC, Ashworth A.

PLoS One. 2009;4(4):e5120. doi: 10.1371/journal.pone.0005120. Epub 2009 Apr 9.

PMID:
19357772
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.

Abbasi M, Lavasanifar A, Uludag H.

Med Res Rev. 2013 Jan;33(1):33-53. doi: 10.1002/med.20244. Epub 2011 Apr 26. Review.

PMID:
21523793
[PubMed - indexed for MEDLINE]
14.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA.

Nature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003. Erratum in: Nature. 2012 Dec 13;492(7428):290.

PMID:
22460905
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Identification of potential synthetic lethal genes to p53 using a computational biology approach.

Wang X, Simon R.

BMC Med Genomics. 2013 Sep 11;6:30. doi: 10.1186/1755-8794-6-30.

PMID:
24025726
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Using large-scale RNAi screens to identify novel drug targets for cancer.

Nijwening JH, Beijersbergen RL.

IDrugs. 2010 Nov;13(11):772-7. Review.

PMID:
21046524
[PubMed - indexed for MEDLINE]
17.

Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).

Telang N, Katdare M.

Oncol Rep. 2011 May;25(5):1195-201. doi: 10.3892/or.2011.1215. Epub 2011 Mar 10. Review.

PMID:
21399881
[PubMed - indexed for MEDLINE]
18.

Alterations of metabolic genes and metabolites in cancer.

Oermann EK, Wu J, Guan KL, Xiong Y.

Semin Cell Dev Biol. 2012 Jun;23(4):370-80. doi: 10.1016/j.semcdb.2012.01.013. Epub 2012 Jan 28. Review.

PMID:
22306135
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro.

Orbán E, Manea M, Marquadt A, Bánóczi Z, Csík G, Fellinger E, Bosze S, Hudecz F.

Bioconjug Chem. 2011 Oct 19;22(10):2154-65. doi: 10.1021/bc2004236. Epub 2011 Oct 5.

PMID:
21950465
[PubMed - indexed for MEDLINE]
20.

Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors.

Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM.

Oncotarget. 2011 May;2(5):378-92.

PMID:
21623005
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk